For joining us here at the Jefferies Healthcare Conference in London. My name is Faisal Khurshid, Senior Biotech Analyst at Jefferies. Really pleased to have with us this morning the management team of PTC Therapeutics. I have with me on stage Matt Klein and Pierre Gravier, and we are going to get into some fun topics across Sephience and other things. Matt, can I ask you to kick it off and just give us a quick intro to the company?
Sure, absolutely. Faisal, thank you for having us. Great to be here. PTC is a global rare disease company that has both R&D and commercial capacity. We have a strong global commercial infrastructure, and 2026 has really been a highly successful year for us, led by this continued successful launch of our oral PKU drug, Sephience. Right now, we closed the third quarter with $182 million in revenue, which is, I think, much stronger than anyone expected. This has been a truly global launch, where we launched it in the U.S., Europe, Japan, and will be in over 20 countries by the end of the year. So, that is off to a great start. We also have very strong R&D capabilities in inflammation, metabolism, and neurology, with research in splicing.
We have the leading oral small molecule splicing platform that really pioneered the field and continues to be a source of valuable programs. Also this year, we set as a goal for the company to become cash flow break-even, and we are absolutely on target to achieve that, which puts us in great position next year to start thinking about moving to sustainable profitability. We also remain in a very strong financial position, closing the third quarter with over $2.1 billion in cash.
Got it. Awesome. Thank you for that overview, Matt. I want to get into the nitty-gritty on Sephience. Can you talk to us about the growth trajectory that you have seen on Sephience so far, and just where you sit today, just to kind of frame it up for us, in terms of number of patients that have tried the drug compared to the TAM available here?
Absolutely. Look, by all measures, we are one year into the Sephience launch now, and by all measures, it has been an incredible success. We set out to, as I mentioned in my opening remarks, to have a global launch, be able to access what we see as a significant size population, 17,000 in the U.S., 58,000 including the U.S. and countries worldwide where we believe we can obtain access. We have a highly differentiated therapy in it being oral, having demonstrated the ability to be effective in the full spectrum of patients, regardless of age, regardless of disease severity, and therefore, had a tremendous opportunity to access this entire market.
Got it.
We also have global commercial infrastructure, which allowed us to basically plug and play in regions all over the world. The story of the first year, in addition to the strong performance in revenue, has been breadth. We have been able to early on penetrate all of the key market segments, whether those be those currently on therapies, those who have never tried therapies, or those who have tried and failed existing therapies, as well as the full age range of patients. We shared that by the second full quarter of launch, we already had prescriptions from 100% of the centers of excellence in the U.S. So, that just tells you how early on we really have gotten wide in terms of the patient base, which now allows us to grow significantly from here. I would say we have had great success early on, but we are still very, very early on.
Just take the U.S., for example, where there is an estimated 17,000 patients, and Kuvan, I think the numbers are about 70% of patients tried Kuvan. We know already that we said we have over 2,000 patients globally at this point in time, but we know that we have only begun to penetrate the entire market. If you consider 17,000 patients, even if you are talking about 70% of those patients trying, we still have a long way to go. Then add on top of it that we have been able to penetrate those 30% who did not try Kuvan. This really sets us up to be in position to continue to penetrate all of those segments, and we still expect, as we have said, steady growth in the U.S. as we continue to move forward and penetrate segments.
Outside the U.S., we expect to have continued growth as we bring new markets, as we get access in new markets, which we expect the next growth to come in 2027.
Got it. Matt, it is always hard to keep investors happy, and I guess with this, the flip side of having such a strong kind of white-hot launch out of the gate is that the question then becomes, to what extent can you sustain that? That has been a little bit of the kind of investor controversy on this
Yeah
especially on the U.S. side, how and if you can sustain the growth clip.
Yeah.
Can you just talk about that a little bit? How should we be thinking about that?
Yeah, 100%. Look, I think we love to look back and say, before we started this launch, most people thought we were going to peak globally at $600 million. We are on a run rate beyond that now, already beyond that in the U.S. alone. I think you have to think about it in several ways. It is hard to imagine a drug with this profile peaking in year one. Also, when you think about the addressable market and how many more patients there is to go in the U.S. So, if you are seeing 17,000 patients in the U.S., just going back to the numbers I mentioned, 17,000 patients in the U.S., 70% of those tried Kuvan. The reason the other 30% did not try Kuvan is because they had mutations that most believe would not respond to Kuvan.
About 25% of our prescriptions so far come from that segment. So, what you are seeing, just look at the numbers. We have got a very long, long way to go in terms of patients trying Kuvan. Absolutely, there was an acceleration out of the gates. That reflects the differentiated profile of the drug, the incredible work our teams did in market development and market penetration. Now we come to this one-year point, and this same team that delivered far beyond anyone's expectations in year one is poised to continue to deliver as we go forward. You basically got a very large pool of patients who have not tried.
You have a track record of success for those who are on the drug, regardless of severity and having benefits in terms of phenylalanine lowering, diet liberalization, neurocognitive benefits, and you have a team that has demonstrated to execute, that has been able to take the lessons from year one and now put in place tailored tactics to ensure that we can continue to penetrate. The benefit of having this breadth of launch and a strong patient base this early is it allows you to make learnings. It allows us to understand on a center-by-center basis, prescriber-by-prescriber basis within each center, understand what we need to do in order to continue to grow at the rate we think we are going to grow. Our commentary has been quite consistent the past few quarters. We expect growth in the U.S. to be steady.
We had that from Q1 to Q2 to Q3, and in Q3, of course, we had summer seasonality. Of course, there will be seasonality around Christmas and Thanksgiving, but in spite of that, we still see this continued growth for quite some time.
Got it. Can I ask just for a little bit more detail on that, right? Because you have all these patients that exist, at least in the U.S. and globally as well, that have previously tried Kuvan and are presumably now off of pharmacotherapy. What do you need to do to kind of bring those patients back into the fold and get them to try Sephience?
Yeah, this is super interesting because when we started the launch, Faisal, the thought was, and a lot of this actually came from prescribers as well, is that the, I hate this term, but everyone uses it, the low-hanging fruit in the launch would be those who were on Kuvan who would switch. Why? Because if you're on a once-a-day oral therapy and there's a new once-a-day oral therapy that is superior, 100% of patients when they switch from Kuvan, branded or generic to Sephience, do better, do much better. That's what the data show. We have head-to-head studies on that. That's not what happened. What happened was the patients who were not on therapy, the patients who never tried therapy, were coming in to get on Sephience. And that was-
Matt, just remind us the split you've seen so far between kind of Kuvan switchers versus kind of not on Kuvan?
Yeah. So it's hard to get the exact numbers, but the numbers we had said early on were about two-thirds of the patients who had tried and failed. We had somewhere around 20%-25% therapy-naive. And our numbers say there's still 2,000 to 2,500 patients still on Kuvan. So, I think we haven't really begun to scratch the surface on that segment. But one of the key learnings are that folks who weren't necessarily on pharmacotherapy, it didn't mean, one, that they weren't attached to the clinic. They often interact with the dieticians because if you're not on therapy, your management is dietary management and nutritional supplements. The other thing that we've leveraged is in 2026, a drug launch looks a little different than it did in the past. Social media is a really big deal.
There's no greater marketing campaign for us than when an individual who's tried Kuvan goes on X or Facebook or Instagram and talks about how, "Just had steak for the first time, enjoying diet I never had, foods I've never had before, having meals with my children that I never had before." These folks are, just because they're not going to clinic, they're still networked with other PKU patients. There's PKU chat groups. There's actually PKU influencers. What we've been able to do is get the message out to those who aren't necessarily coming to clinic often. I think the other thing we've been able to do with the experience now of the early penetration into the therapy-naive individuals is understand their patient journey. Let's learn from that. How did you find out about Sephience? Why did you come in?
When you do that, we're able to take that back and then have tailored plans to go out and continue to penetrate these segments. That's why we're so excited about what's to come. You go through a launch in your first year and you get off to a great start. There's so much we've learned. Of course, we have very capable customer-facing teams who said, "Great, we now have analytics, we have learnings." All of these things come back in, and then you go out the next year and you go to do even better and continue to work. It's all those types of things alongside knowing that there's probably 14,000 to 15,000 patients in the U.S. who have not tried Sephience yet.
Got it. Matt, just to kind of like simplify it a bit, it seems pretty straightforward to me. You still have a couple thousand patients who are on Kuvan who are kind of ripe to switch. You have, at least in the U.S., like a five-digit number of people who-
Yes
are not on therapy and able to get on your drug. What are investors missing? When you kind of, you're having meetings all day
Yeah
What do you think investors don't get about this?
They have to zoom out. I think you have to zoom out and look at the numbers and the reality and understand what happens in a launch. A launch, if you go up to 10,000 feet, you'll see a very smooth straight line up and to the right. But on a week-to-week, quarter-to-quarter basis, there's ebbs and flows in a launch. That's never not been the case. In the summer, we did a global launch. What did we learn in the summer? In July, certain countries, certain clinics aren't open and prescribing. In August, other clinics aren't open and prescribing. Around Labor Day and international meetings in the U.S., those clinics aren't prescribing. Great. So what does that mean? There's puts and takes on a quarter-by-quarter basis. Thanksgiving, well, how many U.S. clinics are going to be prescribing patients on Thursday, Thanksgiving? I'll give you, it's zero.
That I can say with confidence, and probably the same on Christmas. But that's a launch. People have asked a lot about, "Well, you keep saying you think this is a $2 billion plus opportunity." The answer is, yeah, we do. Do the math, the exact math that you're talking about. Are we going to get to $2 billion in one year? No, of course not. But the fact that we have already built this strong base of patients of over 2,000 patients after one full year. We have all this room to go, means we're going to continue growing. We're going to get to those numbers. It's going to take time, as it always does in a launch.
Yeah. I want to ask about that. I love that you read my mind on my next question. In terms of that TAM number, you've said this $2 billion kind of high-level estimate that you've put out there. Just to clarify for us, is that your estimate or what you see as peak for the drug, or is that what you see as the addressable opportunity here? At what point do you modify this assumption, is there?
Yeah. So, look, the reason we've held that number out, and we've said this is not official guidance, we hold it out, is because the opportunity has been so misunderstood from the beginning. As I said, when we started, if you go back to everyone's model, the sell-side models, buy-side models, everyone said, "This is a $500 million-$600 million peak market." Why did they say that? Because that's where Kuvan peaked. Okay, I understand why you would want to analog to another therapy, but one is so differentiated from the other, it's not a very reliable benchmark. So what we felt that we've had to do is have people think differently, not just differently, more realistically for what is the potential opportunity for a differentiated oral rare disease therapy with a TAM of 58,000 in markets where we have infrastructure and we can achieve access.
That's what you get. The next step for us is to give guidance. We'll give guidance in 2027 specifically for Sephience.
Should we expect that in January?
We typically will give guidance in January, so I think that's reasonable to expect we'll give that guidance. Look, I think from our standpoint, we've always tried to do our best in what we believe we can achieve. There's always potential upsides. I think, the other question we get a lot, Faisal, and not to try to read your mind again, but is the ex-U.S. opportunity, which I think people really have a hard time modeling, in part because it's a little bit unpredictable. When we started out, we said, "Look, we've got global commercial capabilities. We understand how to get access in countries, but it takes time." We said, "We're going to have a playbook where we'll go first in Germany and Japan." Why Germany? Because you have the free pricing opportunity. Why Japan?
It's a high-value orphan market where we've achieved net pricing on par with the U.S. and it's fixed for 10 years. That's a very good place to start. We'll then leverage named patient opportunities where we can in European countries, in ex-European and ex-U.S. countries like in the Middle East, like in Latin America. Why? Because we're able to get small numbers of patients early on at price that we set, and then you put the drug in the hands of the key thought leaders in that country so that when you go to have discussions with payers and HTA authorities, you already have internal champions that have a positive experience with your drug. Okay, great. That's what we're doing. Now we're at a point where we're going through the reimbursement discussions in Europe, and I don't have to tell folks that's challenging.
We're very confident that we can do good business there, that we could have high margin profitable businesses in a number of the countries, but it's going to take time to get formal access and pricing. As those countries come on board, we will then have inflection. We look to Q4, what do we expect? Probably pretty steady revenue from Q3. Why? Because we're in Japan, we're in Germany, we're ticking along, and we're going to wait for the next inflections when we start bringing other markets on board. Japan's interesting as well because that's also been a really strong start. As most folks probably know that in Japan, when you're approved, every drug in the first year following approval has to get renewed every month. That goes for a year.
When we hit the one-year mark, it's going to then expand out to a longer period of time, which is when we expect the next big inflection there with Kuvan switches and things like that.
Got it. Matt, I want to get back to that kind of question of like the $2 billion estimate, peak sales estimate you've put out there. Maybe, maybe not in January, you're going to give us a guidance on Sephience.
Yeah, expect the guide. I don't want to be cryptic. We expect to give guidance in January.
Yeah.
We're not going to guide to $2 billion next year, I'll tell you that as well.
Yeah, but you will. I mean, let's just kind of like put a very broad range on it, right? Like your current run rate is like 650, right? Like let's say the range that you might say in January will be somewhere between 650 and maybe double that, right? Like in that ballpark, just to put a really broad range out there.
Yeah, no, look, Faisal, we'll do the numbers, we'll do the work, we'll give the guidance in January. It'll be, again, reasonable what we can do. And to your point, we expect continued growth in the U.S., steady growth, and we expect this to put us exactly on that trajectory towards the $2 billion plus number.
Yeah. Do you feel like that $2 billion is achievable, cautious, or optimistic?
Achievable, that's why we say it.
Got it.
Absolutely. I think we've shown all along that when we message things, it's because we believe it. Let me just say, I think the next step is to give concrete guidance for 2027. We said we weren't going to give guidance in 2026 because we typically don't give guidance until we're through the first full year of launch because there's a lot of unknowns in a launch. There'll be unknowns next year, there'll be a range, and that range will include numbers that we believe we can hit, and there'll always be upsides to that.
Got it. I want to ask about the competitive landscape. Otsuka will have phase III data within the next year. Can you talk about how you're seeing potential competitive entry in this space?
Yeah, absolutely. Otsuka has the kidney-directed therapy, which I think is a very interesting approach. What we've heard is that is a potential approval 2028 or later. I think there's still a lot to learn there. The idea is that you're forcing the kidney to pee out phenylalanine by blocking a nonspecific or non-selective transporter. The risk there is that you're excreting also all these other amino acids that the body needs. I think that what we've heard from a lot of the prescribers is there's a little bit of a concern if I give this and I need to lower phenylalanine a lot, I'm going to have to give back supplements, so I'm going to be in this kind of circle that I'm in now.
That's why I think most have said they really see Sephience as a backbone therapy and adding a kidney-directed therapy on top, where you're asking it to do less and therefore probably get less of the risk of it, and can maybe increase dietary protein and other aspects of disease. I think most folks see that as complementary. The other good thing is, look, with what we have now in terms of the start, we will be the first-line therapy, and we're going to be very well penetrated. I think it will be a nice setup for a disease community that's used to cocktail therapies to now be able to have something that they could add on to a backbone of Sephience.
Got it. Okay. We have a few minutes left. Pierre, we got to pick on you a little bit as well. Matt mentioned the strong cash position and kind of sustainable profitability that you guys are going for. Can you just tell us a little bit about the business development philosophy? I know you did one deal this year. You've spoken about potential capacity to do more here.
Yes. So look, in terms of cash and OpEx, et cetera, so look, we said the first step was to be cash flow breakeven, as Matt Klein mentioned. We are absolutely on track to get there. We closed Q2 with $2.1 billion, and we have capacity, right? I mean, the ST-920 was $100 million upfront for potential BLA stage asset with approval next year. So we still have significant firepower available to us, and we have a global infrastructure that is ready to go. So we are actively looking at things that could accelerate that growth rate and that cash flow positivity. So that is how we think about it, in a very disciplined approach, value-creative assets that we can cast in our infrastructure. Anything, people ask us, "Are you back in gene therapy? Are you going to do gene therapy?" That was very unique in the way we look at business development.
We are not going to go and increase OpEx for phase I assets in gene therapy or things like that.
Got it. So could you describe a little bit more then, because it sounds like you are saying that the Fabry deal might have been a little bit more of a one-off?
I think absolutely. Look, it was very unique, right? I mean, $100 million upfront for BLA-ready, also gene therapy. Those were very unique. We are not chasing the courtrooms, right? Just to be clear. That again came on us, and also for a number of reasons. We actually have a gene therapy. We have an upstream capability that we sell. So we knew how to look at assets. We knew how to look at quality. There are not so many AAV gene therapy approved. So our team had that capabilities. On the Fabry aspect as well, actually, our Chief Business Officer launched Replagal 20 years ago. So there was a lot of things that actually came together here.
I'd also add that the commercial, it was also unique from a commercial standpoint, not only having a large number of individuals with experience in Fabry, but the standard of care enzyme replacement therapy is quite costly. It has its number of significant limitations. In terms of looking, one of the major considerations for gene therapy is, can you get paid for them? If you have data that shows that you have a durable therapy and payers are already paying $400,000-$500,000 a year for an ERT, then the value argument is quite easy. We see this as being not only commercially viable, but really a significant commercial potential.
Got it. I love the timing of the Jefferies conference because we often get to kind of catch folks, like recently after board meetings, as they're thinking about 2027 planning. As you think about next year for the company, you're on a strong growth trajectory with Sephience, cash flow profitability, strong balance sheet. How are you thinking about kind of capital allocation between, you started by mentioning your old splicing platforms. You have internal R&D, you have BD that you've started to do this year. You have the opportunity or at least the capacity to do things like share buybacks. How are you thinking about allocating capital across, broadly these three potential activities?
You mentioned something very interesting at the start. It gives us the full flexibility to operate across each of them. Of course, the business first, we obviously will invest in our pipeline, in new assets are coming on board. That's bread and butter, and that's the business. That's absolutely on target. We don't have to do anything. That's actually the important aspect there, right? Again, it's not that we have to run and do BD just to do BD, just to say, "Oh, look, we deployed capital to do that despite our capacity." It just gives us the full capabilities to do what we want. For the right asset, of course, we'll do something if it comes to us.
If it's an asset where, yeah, ticks the box, near-term commercial, rare disease, you can plug it in, but you have to pay, whatever, 10x multiple and destroy value for sure, we're not going to do that. Actually, that's the important aspect here for us, is we have $2 billion cash, we have cash flow positive, and Sephience, obviously, growth, everything is doing well. We have our own products. That's where we can cast in what we want.
Got it. Just to kind of close, I wanted to tell you guys a little story. I was at marketing a few weeks ago in Europe, met a lot of kind of like long-only investors. Had my comp table in front. I told those investors, I was like, "Just close your eyes for a second. Don't look at my comp sheet. I'm going to tell you about a company. They're on this type of revenue CAGR. They have cash on the balance sheet, double revenue, sustainable profitability, ability to kind of expand their pipeline, do BD, et cetera. What company am I talking about?" And the response was, "Well, it sounds like a really good company. I always struggle to find lower-risk biotech companies." And they were surprised to learn that it was PTC.
Yeah.
What do you think investors are missing about your story? Because I think there's a lot to appreciate from a risk profile perspective that people aren't. Can you just close with telling us what you think people are missing?
Yeah, so two things. One is the company you described, it's pretty rare. That's why people couldn't think of it. It's very rare to see a biotech that has innovative science, its own homemade R&D, global commercial infrastructure, near-term profitability, and $2 billion in cash. That's pretty damn rare. Then if you think that PTC's been around a long time, that's also part of the challenge, that the company was a biotech for 25 years that did a lot of different things, spent a lot of money in things that startup phase biotechs do. I took over as CEO and Pierre took over as CFO a little over three years ago, and we said, "We're going to take this company to the next level. We're going to be focused on what we do in R&D. We're going to leverage a unique, strong global commercial infrastructure.
We're going to redo the balance, to take a broken balance sheet and turn it into a strength, and put the company on a path to cash flow breakeven." When I said that three years ago, people thought I was crazy and that was never going to happen, and yet here we are. We're really proud of all the hard work we've done over the past three years to turn something that was a larger legacy biotech company into a unique commercial stage, valuable, financially strong, financially savvy, high-growth potential biotech company.
Got it. Awesome. Well, congratulations on all the progress, and good luck with the rest of the meeting today, and thank you for being with us.
Thank you.
Thank you.